Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 544

1.

The TRAIL system is over-expressed in breast cancer and FLIP a marker of good prognosis.

Ullenhag GJ, Al-Attar A, Mukherjee A, Green AR, Ellis IO, Durrant LG.

J Cancer Res Clin Oncol. 2014 Sep 18. [Epub ahead of print]

PMID:
25230899
[PubMed - as supplied by publisher]
2.

Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy.

Albarakati N, Abdel-Fatah TM, Doherty R, Russell R, Agarwal D, Moseley P, Perry C, Arora A, Alsubhi N, Seedhouse C, Rakha EA, Green A, Ball G, Chan S, Caldas C, Ellis IO, Madhusudan S.

Mol Oncol. 2014 Aug 27. pii: S1574-7891(14)00183-5. doi: 10.1016/j.molonc.2014.08.001. [Epub ahead of print]

PMID:
25205036
[PubMed - as supplied by publisher]
3.

A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer.

Vollan HK, Rueda OM, Chin SF, Curtis C, Turashvili G, Shah S, Lingjærde OC, Yuan Y, Ng CK, Dunning MJ, Dicks E, Provenzano E, Sammut S, McKinney S, Ellis IO, Pinder S, Purushotham A, Murphy LC, Kristensen VN; METABRIC Group, Brenton JD, Pharoah PD, Børresen-Dale AL, Aparicio S, Caldas C.

Mol Oncol. 2014 Aug 8. pii: S1574-7891(14)00174-4. doi: 10.1016/j.molonc.2014.07.019. [Epub ahead of print]

PMID:
25169931
[PubMed - as supplied by publisher]
Free Article
4.

A study of ductal versus non-ductal invasive breast carcinomas in older women: long-term clinical outcome and comparison with their younger counterparts.

Mathew J, Lee S, Syed BM, Morgan DA, Ellis IO, Cheung KL.

Breast Cancer Res Treat. 2014 Oct;147(3):671-4. doi: 10.1007/s10549-014-3094-4. Epub 2014 Aug 23.

PMID:
25148877
[PubMed - in process]
5.

Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer.

Rudraraju B, Droog M, Abdel-Fatah TM, Zwart W, Giannoudis A, Malki MI, Moore D, Patel H, Shaw J, Ellis IO, Chan S, Brooke GN, Nevedomskaya E, Lo Nigro C, Carroll J, Coombes RC, Bevan C, Ali S, Palmieri C.

Breast Cancer Res Treat. 2014 Sep;147(2):295-309. doi: 10.1007/s10549-014-3098-0. Epub 2014 Aug 22.

PMID:
25141981
[PubMed - in process]
6.

Is There a Role for Base Excision Repair in Estrogen/Estrogen Receptor-Driven Breast Cancers?

Abdel-Fatah TM, Perry C, Arora A, Thompson N, Doherty R, Moseley PM, Green AR, Chan SY, Ellis IO, Madhusudan S.

Antioxid Redox Signal. 2014 Sep 22. [Epub ahead of print]

PMID:
25111287
[PubMed - as supplied by publisher]
7.

ERK1/2 is related to oestrogen receptor and predicts outcome in hormone-treated breast cancer.

Jerjees DA, Alabdullah M, Alkaabi M, Abduljabbar R, Muftah A, Nolan C, Green AR, Ellis IO, Rakha EA.

Breast Cancer Res Treat. 2014 Aug;147(1):25-37. doi: 10.1007/s10549-014-3066-8. Epub 2014 Aug 2.

PMID:
25085753
[PubMed - in process]
8.

Biological characteristics and clinical outcome of triple negative primary breast cancer in older women - comparison with their younger counterparts.

Syed BM, Green AR, Nolan CC, Morgan DA, Ellis IO, Cheung KL.

PLoS One. 2014 Jul 7;9(7):e100573. doi: 10.1371/journal.pone.0100573. eCollection 2014.

PMID:
24999743
[PubMed - in process]
Free PMC Article
9.

Therapeutic targeting of integrin αvβ6 in breast cancer.

Moore KM, Thomas GJ, Duffy SW, Warwick J, Gabe R, Chou P, Ellis IO, Green AR, Haider S, Brouilette K, Saha A, Vallath S, Bowen R, Chelala C, Eccles D, Tapper WJ, Thompson AM, Quinlan P, Jordan L, Gillett C, Brentnall A, Violette S, Weinreb PH, Kendrew J, Barry ST, Hart IR, Jones JL, Marshall JF.

J Natl Cancer Inst. 2014 Jun 28;106(8). pii: dju169. doi: 10.1093/jnci/dju169. Print 2014 Aug.

PMID:
24974129
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers.

Abdel-Fatah T, Arora A, Agarwal D, Moseley P, Perry C, Thompson N, Green AR, Rakha E, Chan S, Ball G, Ellis IO, Madhusudan S.

Breast Cancer Res Treat. 2014 Jul;146(2):309-20. doi: 10.1007/s10549-014-3035-2. Epub 2014 Jun 28.

PMID:
24972688
[PubMed - in process]
11.

The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin β₁.

Xu Y, Zhang H, Lit LC, Grothey A, Athanasiadou M, Kiritsi M, Lombardo Y, Frampton AE, Green AR, Ellis IO, Ali S, Lenz HJ, Thanou M, Stebbing J, Giamas G.

Sci Signal. 2014 Jun 17;7(330):ra58. doi: 10.1126/scisignal.2005170.

PMID:
24939894
[PubMed - in process]
12.

Immunoglobulin free light chains are biomarkers of poor prognosis in basal-like breast cancer and are potential targets in tumor-associated inflammation.

Groot Kormelink T, Powe DG, Kuijpers SA, Abudukelimu A, Fens MH, Pieters EH, Kassing van der Ven WW, Habashy HO, Ellis IO, Blokhuis BR, Thio M, Hennink WE, Storm G, Redegeld FA, Schiffelers RM.

Oncotarget. 2014 May 30;5(10):3159-67.

PMID:
24931643
[PubMed - in process]
Free PMC Article
13.

Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.

Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M, Earl HM, Poole CJ, Hiller L, Dunn JA, Bowden SJ, Twelves C, Bartlett JM, Mahmoud SM, Rakha E, Ellis IO, Liu S, Gao D, Nielsen TO, Pharoah PD, Caldas C.

Ann Oncol. 2014 Aug;25(8):1536-43. doi: 10.1093/annonc/mdu191. Epub 2014 Jun 9.

PMID:
24915873
[PubMed - in process]
14.

KSR1 regulates BRCA1 degradation and inhibits breast cancer growth.

Stebbing J, Zhang H, Xu Y, Lit LC, Green AR, Grothey A, Lombardo Y, Periyasamy M, Blighe K, Zhang W, Shaw JA, Ellis IO, Lenz HJ, Giamas G.

Oncogene. 2014 Jun 9;0. doi: 10.1038/onc.2014.129. [Epub ahead of print]

PMID:
24909178
[PubMed - as supplied by publisher]
15.

Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer.

Abdel-Fatah TM, Russell R, Albarakati N, Maloney DJ, Dorjsuren D, Rueda OM, Moseley P, Mohan V, Sun H, Abbotts R, Mukherjee A, Agarwal D, Illuzzi JL, Jadhav A, Simeonov A, Ball G, Chan S, Caldas C, Ellis IO, Wilson DM 3rd, Madhusudan S.

Mol Oncol. 2014 Oct;8(7):1326-38. doi: 10.1016/j.molonc.2014.04.009. Epub 2014 May 13.

PMID:
24880630
[PubMed - in process]
16.

Papillary and neuroendocrine breast lesions: the WHO stance.

Tan PH, Schnitt SJ, van de Vijver MJ, Ellis IO, Lakhani SR.

Histopathology. 2014 May 21. doi: 10.1111/his.12463. [Epub ahead of print]

PMID:
24845113
[PubMed - as supplied by publisher]
17.

Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study.

Aleskandarany MA, Negm OH, Green AR, Ahmed MA, Nolan CC, Tighe PJ, Ellis IO, Rakha EA.

Breast Cancer Res Treat. 2014 Jun;145(2):339-48. doi: 10.1007/s10549-014-2927-5. Epub 2014 Apr 26.

PMID:
24771047
[PubMed - in process]
18.

Molecular profiling of breast cancer in Nigerian women identifies an altered p53 pathway as a major mechanism underlying its poor prognosis compared with British counterpart.

Agboola AO, Banjo AA, Anunobi CC, Ayoade BA, Deji-Agboola AM, Musa AA, Abdel-Fatah T, Nolan CC, Rakha EA, Ellis IO, Green AR.

Malays J Pathol. 2014 Apr;36(1):3-17.

PMID:
24763230
[PubMed - indexed for MEDLINE]
Free Article
19.

Prognostic significance of lymphatic invasion in lymph node-positive breast carcinoma: findings from a large case series with long-term follow-up using immunohistochemical endothelial marker.

Mohammed RA, Menon S, Martin SG, Green AR, Paish EC, Ellis IO.

Mod Pathol. 2014 Apr 25. doi: 10.1038/modpathol.2014.60. [Epub ahead of print]

PMID:
24762542
[PubMed - as supplied by publisher]
20.

HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer.

Abdel-Fatah TM, McArdle SE, Johnson C, Moseley PM, Ball GR, Pockley AG, Ellis IO, Rees RC, Chan SY.

Br J Cancer. 2014 May 13;110(10):2450-61. doi: 10.1038/bjc.2014.168. Epub 2014 Apr 22.

PMID:
24755885
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk